APA
Rammensee H., Wiesmüller K., Chandran P. A., Zelba H., Rusch E., Gouttefangeas C., Kowalewski D. J., Di Marco M., Haen S. P., Walz J. S., Gloria Y. C., Bödder J., Schertel J., Tunger A., Müller L., Kießler M., Wehner R., Schmitz M., Jakobi M., Schneiderhan-Marra N., Klein R., Laske K., Artzner K., Backert L., Schuster H., Schwenck J., Weber A. N. R., Pichler B. J., Kneilling M., la Fougère C., Forchhammer S., Metzler G., Bauer J., Weide B., Schippert W., Stevanović S. & Löffler M. W. (20200702). A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. : Journal for immunotherapy of cancer.
Chicago
Rammensee Hans-Georg, Wiesmüller Karl-Heinz, Chandran P Anoop, Zelba Henning, Rusch Elisa, Gouttefangeas Cécile, Kowalewski Daniel J, Di Marco Moreno, Haen Sebastian P, Walz Juliane S, Gloria Yamel Cardona, Bödder Johanna, Schertel Jill-Marie, Tunger Antje, Müller Luise, Kießler Maximilian, Wehner Rebekka, Schmitz Marc, Jakobi Meike, Schneiderhan-Marra Nicole, Klein Reinhild, Laske Karoline, Artzner Kerstin, Backert Linus, Schuster Heiko, Schwenck Johannes, Weber Alexander N R, Pichler Bernd J, Kneilling Manfred, la Fougère Christian, Forchhammer Stephan, Metzler Gisela, Bauer Jürgen, Weide Benjamin, Schippert Wilfried, Stevanović Stefan and Löffler Markus W. 20200702. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. : Journal for immunotherapy of cancer.
Harvard
Rammensee H., Wiesmüller K., Chandran P. A., Zelba H., Rusch E., Gouttefangeas C., Kowalewski D. J., Di Marco M., Haen S. P., Walz J. S., Gloria Y. C., Bödder J., Schertel J., Tunger A., Müller L., Kießler M., Wehner R., Schmitz M., Jakobi M., Schneiderhan-Marra N., Klein R., Laske K., Artzner K., Backert L., Schuster H., Schwenck J., Weber A. N. R., Pichler B. J., Kneilling M., la Fougère C., Forchhammer S., Metzler G., Bauer J., Weide B., Schippert W., Stevanović S. and Löffler M. W. (20200702). A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. : Journal for immunotherapy of cancer.
MLA
Rammensee Hans-Georg, Wiesmüller Karl-Heinz, Chandran P Anoop, Zelba Henning, Rusch Elisa, Gouttefangeas Cécile, Kowalewski Daniel J, Di Marco Moreno, Haen Sebastian P, Walz Juliane S, Gloria Yamel Cardona, Bödder Johanna, Schertel Jill-Marie, Tunger Antje, Müller Luise, Kießler Maximilian, Wehner Rebekka, Schmitz Marc, Jakobi Meike, Schneiderhan-Marra Nicole, Klein Reinhild, Laske Karoline, Artzner Kerstin, Backert Linus, Schuster Heiko, Schwenck Johannes, Weber Alexander N R, Pichler Bernd J, Kneilling Manfred, la Fougère Christian, Forchhammer Stephan, Metzler Gisela, Bauer Jürgen, Weide Benjamin, Schippert Wilfried, Stevanović Stefan and Löffler Markus W. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. : Journal for immunotherapy of cancer. 20200702.